Anti-Gp9 / Glycoprotein 9 / CD42a

Adding 0.2 ml of distilled water will yield a concentration of 500 ug/ml. The Gp9 antibody targets Platelet glycoprotein IX, a membrane glycoprotein encoded by the GP9 gene and an essential component of the platelet glycoprotein Ib-IX-V receptor complex. This complex mediates platelet adhesion to subendothelial von Willebrand factor (vWF) following vascular injury, initiating platelet activation and thrombus formation. Platelet glycoprotein IX, together with glycoproteins Ibalpha, Ibbeta, and V, forms the primary receptor responsible for platelet tethering under high shear conditions. The Gp9 antibody provides a vital tool for studying platelet adhesion mechanisms, receptor assembly, and bleeding disorders associated with GPIb-IX-V dysfunction.Platelet glycoprotein IX is a small single-pass transmembrane protein that stabilizes the larger GPIbalpha subunit and ensures correct receptor complex formation. Mutations in the GP9 gene cause Bernard-Soulier syndrome, a rare autosomal recessive bleeding disorder characterized by macrothrombocytopenia and defective platelet adhesion. The Gp9 antibody is essential for diagnosing and researching this condition, as it allows detection of protein expression and complex assembly defects in patient samples and experimental models.In normal hemostasis, GPIb-IX-V engagement with von Willebrand factor triggers intracellular signaling events that activate integrins and promote platelet aggregation. The Gp9 antibody supports studies that dissect these pathways, clarifying how alterations in complex composition affect receptor function. In addition to its hemostatic role, Platelet glycoprotein IX contributes to thrombo-inflammatory responses, vascular repair, and platelet-leukocyte interactions. Using the Gp9 antibody, researchers can quantify expression and localization on the platelet surface and explore its involvement in inflammation and cardiovascular disease.The Gp9 antibody performs effectively in flow cytometry, western blotting, and immunofluorescence. It provides clear detection of Platelet glycoprotein IX in platelets, megakaryocytes, and hematopoietic progenitors. Studies employing this antibody help define the molecular architecture of the GPIb-IX-V complex and its contribution to platelet activation signaling. By facilitating these analyses, the Gp9 antibody aids both basic research and clinical evaluation of platelet receptor disorders.NSJ Bioreagents provides the Gp9 antibody as a high-specificity, validated reagent for platelet biology and hemostasis research. It supports investigations into receptor complex assembly, thrombosis, and genetic platelet disorders. Through consistent detection and compatibility with multiple assay types, the Gp9 antibody helps advance understanding of platelet adhesion mechanisms and their significance in health and disease.